Connect Biopharmaceuticals

Connect Biopharmaceuticals is a clinical-stage company that discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. They identify and advance our drug candidates through in-house discovery and in-licensing while leveraging qualified CROs for further development. The company successfully completed a phase I clinical trial study on our leading program CBP-307, a novel and selective second-generation S1P1 (a G-protein coupled receptor -GPCR) modulator for the treatment of a range of autoimmune disorders, including multiple sclerosis, inflammatory bowel disease, and psoriasis.

Connect Biopharmaceuticals currently conducting two phases 2 clinical studies in patients with ulcerative colitis and Crohn's disease with their lead drug candidate CBP-307. It also concluding a phase 1 study of our second drug candidate CBP-201 in healthy subjects, with a phase 1b study in atopic dermatitis patients expected to commence in Q1, 2019.

Connect Biopharmaceuticals was founded in 2012 and is headquartered in Taichang, China.

Connect Biopharmaceuticals headquartered in Asia, operates in the Biotechnology, Health Care, Medical, Therapeutics, Clinical Trials sector. The company focuses on Biotechnology and has secured $15.6B in funding across 80 round(s). With a team of 101-250 employees, Connect Biopharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - Connect Biopharmaceuticals, raised $5.0M. Discover more about their projects, partnerships, and impact on our platform.